291
Views
10
CrossRef citations to date
0
Altmetric
Articles

Occurrence of deoxynivalenol in an elderly cohort in the UK: a biomonitoring approach

ORCID Icon, , , , ORCID Icon, , , , , , , , & show all
Pages 2032-2044 | Received 17 Apr 2018, Accepted 07 Jul 2018, Published online: 17 Aug 2018

References

  • Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. 2005. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 113(2):192–200.
  • Brera C, Santis B, Debegnach F, Miano B, Moretti G, Lanzone A, Del Sordo G, Buonsenso D, Chiaretti A, Hardie L, et al. 2015. Experimental study of deoxynivalenol biomarkers in urine. European Food Safety Authority (EFSA) Supporting Publications. EN–81. doi:10.2903/sp.efsa.2015.EN-818
  • Bretz M, Beyer M, Cramer B, Knecht A, Humpf HU. 2006. Thermal degradation of the Fusarium mycotoxin deoxynivalenol. J Agric Food Chem. 54:6445–6451.
  • Bullerman LB, Bianchini A. 2007. Stability of mycotoxins during food processing. Int J Food Microbiol. 119(1–2):140–146.
  • Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, De Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. 2011. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 108(Suppl 1):4586–4591. doi:10.1073/pnas.1000097107
  • Clark ES, Flannery BM, Gardner EM, Pestka JJ. 2015. High sensitivity of aged mice to deoxynivalenol (vomitoxin)-induced anorexia corresponds to elevated proinflammatory cytokine and satiety hormone responses. Toxins (Basel). 7:4199–4215.
  • Drewnowski A. 2000. Sensory control of energy density at different life stages. Proc Nutr Soc. 59:239–244.
  • Etzel RA. 2006. What the primary care pediatrician should know about syndromes associated with exposures to mycotoxins. Curr Probl Pediatr Adolesc Health Care. 36:282–305.
  • [EFSA] European Food Safety Authority. 2013. Deoxynivalenol in food and feed: occurrence and exposure. EFSA J. 11:2013.
  • Ezekiel CN, Warth B, Ogara IM, Abia WA, Ezekiel VC, Atehnkeng J, Sulyok M, Turne PC, Tayo GO, Krska R, et al. 2014. Mycotoxin exposure in rural residents in northern Nigeria: a pilot study using multi-urinary biomarkers. Environ Int. 66:138–145.
  • Föllmann W, Ali N, Blaszkewicz M, Degen GH. 2016. Biomonitoring of mycotoxins in urine: pilot study in mill workers. J Toxicol Environ Health A. 79:1015–1025.
  • Gerding J, Ali N, Schwartzbord J, Cramer B, Brown DL, Degen GH, Humpf HU. 2015. A comparative study of the human urinary mycotoxin excretion patterns in Bangladesh, Germany, and Haiti using a rapid and sensitive LC-MS/MS approach. Mycotoxin Res. 31:127–136.
  • Gerding J, Cramer B, Humpf HU. 2014. Determination of mycotoxin exposure in Germany using an LC-MS/MS multibiomarker approachю. Mol Nutr Food Res. 58(12):2358–2368.
  • Gratz SW, Richardson AJ, Duncan G, Holtrop G. 2014. Annual variation of dietary deoxynivalenol exposure during years of different Fusarium prevalence: a pilot biomonitoring study. Food Addit Contam Part Chem Anal Control Expo Risk Assess. 31(9):1579–1585.
  • Heyndrickx E, Sioen I, Huybrechts B, Callebaut A, De Henauw S, De Saeger S. 2015. Human biomonitoring of multiple mycotoxins in the Belgian population: results of the BIOMYCO study. Environ Int. 84:82–89.
  • [JECFA] Joint Expert Committee on Food and Additives. 2010. Evaluation of certain food additives and contaminants. In Report of the Seventy-Second Meeting of the Joint FAO/WHO Expert Committee on Food Additives. In WHO Technical Report Series, edited by World Health Organization.
  • Mangoni AA, Jackson SH 2004. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 57(6–14). doi:10.1046/j.1365-2125.2003.02007.x
  • Marin S, Ramos AJ, Cano-Sancho G, Sanchis V 2013. Mycotoxins: occurrence, toxicology, and exposure assessment. Food Chem Toxicol. 60(218–37). doi:10.1016/j.fct.2013.07.047
  • Martone AM, Onder G, Vetrano DL, Ortolani E, Tosato M, Marzetti E, Landi F. 2013. Anorexia of aging: a modifiable risk factor for frailty. Nutrients. 5:4126–4133.
  • Oldenburg E, Schittenhelm S. 2012. Effect of plant water deficit on the deoxynivalenol concentration in Fusarium-infected maize kernels. Mycotoxin Res. 28(4):229–236.
  • Papageorgiou M, Wells L, Williams C, White K, De Santis B, Liu Y, Debegnach F, Miano B, Moretti G, Greetham S, et al. 2018. Assessment of urinary deoxynivalenol biomarkers in UK children and adolescents. Toxins (Basel). 10(2):50. doi:10.3390/toxins10020050
  • Pestka JJ. 2010. Deoxynivalenol: mechanisms of action, human exposure, and toxicological relevance. Arch Toxicol. 84:663–679.
  • Pestka JJ, Smolinski AT. 2005. Deoxynivalenol: toxicology and potential effects on humans. J Toxicol Environ Health B Crit Rev. 8:39–69.
  • Rodriguez-Carrasco Y, Molto JC, Manes J, Berrada H. 2014. Development of a GC-MS/MS strategy to determine 15 mycotoxins and metabolites in human urine. Talanta. 128:125–131.
  • Scudamore KA, Hazel CM, Patel S, Scriven F. 2009. Deoxynivalenol and other Fusarium mycotoxins in bread, cake, and biscuits produced from UK-grown wheat under commercial and pilot scale conditions. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 26:1191–1198.
  • Shephard GS, Burger HM, Gambacorta L, Gong YY, Krska R, Rheeder JP, Solfrizzo M, Srey C, Sulyok M, Visconti A, et al. 2013. Multiple mycotoxin exposure determined by urinary biomarkers in rural subsistence farmers in the former Transkei, South Africa. Food Chem Toxicol. 62:217–225.
  • Solfrizzo M, Gambacorta L, Visconti A. 2014. Assessment of multi-mycotoxin exposure in southern Italy by urinary multi-biomarker determination. Toxins (Basel). 6:523–538.
  • Talley NJ, O’Keefe EA, Zinsmeister AR, Melton LJ. 1992. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology. 102:895–901.
  • Turner PC, Burley VJ, Rothwell JA, White KL, Cade JE, Wild CP. 2008. Deoxynivalenol: rationale for development and application of a urinary biomarker. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 25:864–871.
  • Turner PC, Hopton RP, Lecluse Y, White KL, Fisher J, Cade JE, Wild CP. 2011a. Assessment of deoxynivalenol metabolite profiles in UK adults. Food Chem Toxicol. 49:132–135.
  • Turner PC, Hopton RP, Lecluse Y, White KL, Fisher J, Lebailly P. 2010a. Determinants of urinary deoxynivalenol and de-epoxy deoxynivalenol in male farmers from Normandy, France. J Agric Food Chem. 58:5206–5212.
  • Turner PC, Ji BT, Shu XO, Zheng W, Chow WH, Gao YT, Hardie LJ. 2011b. A biomarker survey of urinary deoxynivalenol in China: the Shanghai women’s health study. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 28:1220–1223.
  • Turner PC, White KL, Burley VJ, Hopton RP, Rajendram A, Fisher J, Cade JE, Wild CP. 2010b. A comparison of deoxynivalenol intake and urinary deoxynivalenol in UK adults. Biomarkers. 15:553–562.
  • Wakimoto P, Block G. 2001. Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Gerontol A Biol Sci Med Sci. 56:65–80.
  • Wallin S, Gambacorta L, Kotova N, Lemming EW, Nalsen C, Solfrizzo M, Olsen M. 2015. Biomonitoring of concurrent mycotoxin exposure among adults in Sweden through urinary multi-biomarker analysis. Food Chem Toxicol. 83:133–139.
  • Warth B, Sulyok M, Fruhmann P, Berthiller F, Schuhmacher R, Hametner C, Adam G, Frohlich J, Krska R. 2012. Assessment of human deoxynivalenol exposure using an LC-MS/MS based biomarker method. Toxicol Lett. 211:85–90.
  • Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, Debegnach F, Moretti G, Greetham S, Brera C, et al. 2016. Determination of deoxynivalenol in the urine of pregnant women in the UK. Toxins (Basel). 8:306.
  • Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, Debegnach F, Moretti G, Greetham S, Brera C, et al. 2017. Deoxynivalenol biomarkers in the urine of UK vegetarians. Toxins (Basel). 9:196.
  • Wu Q, Dohnal V, Huang L, Kuca K, Yuan Z. 2010. Metabolic pathways of trichothecenes. Drug Metab Rev. 42:250–267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.